Is Flexeril Neurotoxic?
Flexeril (cyclobenzaprine) is not directly neurotoxic, but it can cause significant CNS adverse effects including sedation, delirium, and anticholinergic toxicity, particularly in older adults and in overdose situations.
Key Safety Concerns
CNS Effects in Therapeutic Use
Cyclobenzaprine causes neurotoxicity-related adverse effects rather than direct structural neurotoxicity. The 2019 AGS Beers Criteria explicitly lists cyclobenzaprine among muscle relaxants that should be avoided in older adults due to anticholinergic effects, sedation, and increased risk of fractures 1. The guideline notes these agents have "questionable effectiveness" for chronic pain and are "poorly tolerated" with high CNS adverse effect risks 2.
Overdose Manifestations
The FDA label clearly outlines CNS toxicity in overdose 3:
- Most common effects: drowsiness and tachycardia
- Neurologic manifestations: tremor, agitation, coma, ataxia, slurred speech, confusion, dizziness, hallucinations
- Rare but critical: seizures and neuroleptic malignant syndrome
- Important: CNS depression can deteriorate abruptly, requiring early intubation consideration
However, cyclobenzaprine does NOT produce the life-threatening cardiovascular or neurologic effects typical of tricyclic antidepressants despite structural similarity 4, 5. A five-year multicenter review of 402 pure cyclobenzaprine ingestions found no deaths, no seizures, and no life-threatening dysrhythmias, with lethargy and anticholinergic effects being most prominent 5.
Serotonin Syndrome Risk
A critical neurotoxic concern is serotonin syndrome when cyclobenzaprine is combined with other serotonergic drugs 6, 7. Case reports document severe serotonin syndrome with:
- Delirium and hyperkinetic movement disorders when combined with opioids 6
- Severe autonomic instability and agitation when combined with phenelzine or duloxetine 7
- Symptoms typically start within hours and resolve within 48-72 hours of discontinuation
Clinical Recommendations
Avoid in High-Risk Populations
- Older adults: Not recommended due to substantially increased plasma concentrations and half-life 3
- Hepatic impairment: Contraindicated in mild, moderate, or severe hepatic dysfunction 3
- Chronic pain: No evidence of efficacy; potential for adverse effects outweighs benefits 2
When Prescribed
- Monitor closely for anticholinergic effects (confusion, urinary retention, dry mouth)
- Screen for drug interactions, particularly with SSRIs, SNRIs, MAOIs, tramadol, or other serotonergic agents
- Limit duration: Approved only for acute musculoskeletal pain, not chronic use
- Watch for CNS depression: sedation, dizziness, cognitive impairment
Overdose Management
If overdose suspected 3:
- Obtain ECG immediately and initiate cardiac monitoring
- Gastric lavage followed by activated charcoal
- Monitor for at least 4 hours (all symptomatic cases become symptomatic within this window 5)
- Serum alkalinization for QRS widening
- Benzodiazepines for seizures (though rare)
- Avoid physostigmine except for life-threatening symptoms unresponsive to other therapies
Common Pitfalls
- Assuming TCA-like cardiotoxicity: Unlike tricyclic antidepressants, cyclobenzaprine rarely causes wide QRS or ventricular dysrhythmias even in overdose 4
- Missing serotonin syndrome: Always review medication list for serotonergic drugs before prescribing
- Prescribing for chronic pain: No evidence supports this use, and risks increase with prolonged exposure 2
- Underestimating elderly vulnerability: Pharmacokinetics are dramatically altered in older adults 3